Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $22.80.

ZVRA has been the topic of several recent analyst reports. HC Wainwright set a $26.00 target price on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Cantor Fitzgerald dropped their price objective on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Tuesday, October 14th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th.

Insider Activity

In related news, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction on Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the transaction, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at $2,402,213.12. This represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $8,676,000. Rubric Capital Management LP grew its stake in Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares during the period. Royce & Associates LP acquired a new position in shares of Zevra Therapeutics during the third quarter worth approximately $6,574,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares in the last quarter. Finally, Nantahala Capital Management LLC grew its position in Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares during the period. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $8.34 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The company has a 50 day simple moving average of $8.92 and a two-hundred day simple moving average of $9.67. The company has a market capitalization of $469.54 million, a PE ratio of 17.74 and a beta of 1.08.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The firm had revenue of $26.06 million for the quarter, compared to the consensus estimate of $26.64 million. Research analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.